Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Research | December 09, 2025 | December 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 09, 2025 · Filed December 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,833 |
Reported balance
After 2025-12-09 transaction · row 1
1 source rowRow 1 · 2025-12-09 · Tax withholding · Disposed 4,229 · Balance 47,833 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 4,375 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,375 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2025 Filed Dec 11, 2025 21:32 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 4,229 | $701.51 | $2,966,685.79 |
DisclosureSEC source: 0001796226-25-000009 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,833 Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,699 | $712.94 | $1,211,285.06 |
DisclosureSEC source: 0001796226-25-000007 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,062 Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 18,315 | $0.00 Strike: $726.71 | $0.00 |
DisclosureSEC source: 0001796226-25-000007 · edgardoc.xml · derivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,315 Underlying: Common Stock · 18,315 shares Expires 2035-12-05 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 3,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001796226-25-000007 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,761 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 5, 2027 and 50% on December 5, 2029. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001796226-25-000005 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,046 Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001796226-25-000005 · edgardoc.xml · derivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 32,490 | $648.82 | $21,080,161.80 |
DisclosureSEC source: 0001796226-25-000005 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,584 Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 35,000 | $555.67 | $19,448,450.00 |
DisclosureSEC source: 0001796226-25-000005 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,054 | $730.81 | $770,273.74 |
DisclosureSEC source: 0001968202-24-000139 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,074 Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 492 | $787.00 | $387,204.00 |
DisclosureSEC source: 0001968202-24-000137 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,128 Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,472 | $0.00 Strike: $771.64 | $0.00 |
DisclosureSEC source: 0001968202-24-000137 · edgardoc.xml · derivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,472 Underlying: Common Stock · 13,472 shares Expires 2034-12-06 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 3,499 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000137 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,620 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 6, 2026 and 50% on December 6, 2028. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000134 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,121 Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 331 | $1,159.69 | $383,857.39 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 20 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,306 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F14 · price: Represents volume-weighted average price of sales of 331 shares of Company stock on August 14, 2024 at prices ranging from $1,159.21 to $1,159.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 189 | $1,158.78 | $219,009.42 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 19 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,637 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F13 · price: Represents volume-weighted average price of sales of 189 shares of Company stock on August 14, 2024 at prices ranging from $1,158.53 to $1,158.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 178 | $1,157.41 | $206,018.98 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 18 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,826 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F12 · price: Represents volume-weighted average price of sales of 178 shares of Company stock on August 14, 2024 at prices ranging from $1,157.13 to $1,157.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,016 | $1,156.43 | $1,174,932.88 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 17 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,004 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F11 · price: Represents volume-weighted average price of sales of 1,016 shares of Company stock on August 14, 2024 at prices ranging from $1,156.06 to $1,156.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 402 | $1,155.76 | $464,615.52 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 16 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,020 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F10 · price: Represents volume-weighted average price of sales of 402 shares of Company stock on August 14, 2024 at prices ranging from $1,155.04 to $1,155.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 777 | $1,154.66 | $897,170.82 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 15 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,422 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F9 · price: Represents volume-weighted average price of sales of 777 shares of Company stock on August 14, 2024 at prices ranging from $1,154.05 to $1,154.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 987 | $1,153.74 | $1,138,741.38 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 14 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,199 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F8 · price: Represents volume-weighted average price of sales of 987 shares of Company stock on August 14, 2024 at prices ranging from $1,153.07 to $1,153.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 197 | $1,152.36 | $227,014.92 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 13 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,186 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F7 · price: Represents volume-weighted average price of sales of 197 shares of Company stock on August 14, 2024 at prices ranging from $1,152.27 to $1,152.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 185 | $1,151.46 | $213,020.10 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 12 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,383 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F6 · price: Represents volume-weighted average price of sales of 185 shares of Company stock on August 14, 2024 at prices ranging from $1,151.09 to $1,151.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 844 | $1,150.41 | $970,946.04 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,568 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F5 · price: Represents volume-weighted average price of sales of 844 shares of Company stock on August 14, 2024 at prices ranging from $1,150.10 to $1,150.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 294 | $1,149.60 | $337,982.40 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 10 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,412 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F4 · price: Represents volume-weighted average price of sales of 294 shares of Company stock on August 14, 2024 at prices ranging from $1,149.13 to $1,149.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 537 | $1,148.52 | $616,755.24 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,706 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F3 · price: Represents volume-weighted average price of sales of 537 shares of Company stock on August 14, 2024 at prices ranging from $1,148.06 to $1,148.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 51 | $1,146.60 | $58,476.60 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,243 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 148 | $1,145.58 | $169,545.84 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,294 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F2 · price: Represents volume-weighted average price of sales of 148 shares of Company stock on August 14, 2024 at prices ranging from $1,145.33 to $1,145.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 45 | $1,144.89 | $51,520.05 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,442 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 79 | $1,143.28 | $90,319.12 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,487 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 48 | $1,142.94 | $54,861.12 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,566 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 55 | $1,140.31 | $62,717.05 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,614 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · derivative · entry 22 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F15 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 13,637 | $1,141.49 | $15,566,499.13 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,669 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 20,000 | $399.66 | $7,993,200.00 |
DisclosureSEC source: 0001968202-24-000119 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 196 | $968.20 | $189,767.20 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 16 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,306 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F12 · price: Represents volume-weighted average price of sales of 196 shares of Company stock on March 14, 2024 at prices ranging from $968.15 to $968.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 17 | $966.30 | $16,427.10 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 15 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,502 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 78 | $965.51 | $75,309.78 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 14 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,519 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F11 · price: Represents volume-weighted average price of sales of 78 shares of Company stock on March 14, 2024 at prices ranging from $965.26 to $965.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $962.87 | $962.87 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 13 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,597 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 47 | $961.74 | $45,201.78 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 12 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,598 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 512 | $959.36 | $491,192.32 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,645 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F10 · price: Represents volume-weighted average price of sales of 512 shares of Company stock on March 14, 2024 at prices ranging from $959.13 to $959.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 477 | $958.34 | $457,128.18 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 10 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,157 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F9 · price: Represents volume-weighted average price of sales of 477 shares of Company stock on March 14, 2024 at prices ranging from $958.06 to $958.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 730 | $957.35 | $698,865.50 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,634 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F8 · price: Represents volume-weighted average price of sales of 730 shares of Company stock on March 14, 2024 at prices ranging from $957.02 to $957.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,108 | $956.34 | $1,059,624.72 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,364 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F7 · price: Represents volume-weighted average price of sales of 1,108 shares of Company stock on March 14, 2024 at prices ranging from $956.08 to $956.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 545 | $955.54 | $520,769.30 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,472 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F6 · price: Represents volume-weighted average price of sales of 545 shares of Company stock on March 14, 2024 at prices ranging from $955.02 to $955.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 870 | $954.66 | $830,554.20 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,017 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F5 · price: Represents volume-weighted average price of sales of 870 shares of Company stock on March 14, 2024 at prices ranging from $954.01 to $954.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 576 | $953.77 | $549,371.52 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,887 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F4 · price: Represents volume-weighted average price of sales of 576 shares of Company stock on March 14, 2024 at prices ranging from $953.30 to $953.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 444 | $952.40 | $422,865.60 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,463 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F3 · price: Represents volume-weighted average price of sales of 444 shares of Company stock on March 14, 2024 at prices ranging from $952.00 to $952.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 182 | $951.92 | $173,249.44 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,907 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F2 · price: Represents volume-weighted average price of sales of 182 shares of Company stock on March 14, 2024 at prices ranging from $951.89 to $951.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · derivative · entry 18 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F13 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 14,217 | $971.82 | $13,816,364.94 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,089 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.